Recital 3, Directive (EU) 2001/83

In forcecited 24×

However, this objective must be attained by means which will not hinder the development of the pharmaceutical industry or trade in medicinal products within the Community.

The 10 that are cited most themselves, of 24.

  • Judgment of the Court (First Chamber) of 15 November 2007. Commission of the European Communities v Federal Republic of Germany.Decision

    The second to the fifth recitals in the preamble to Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67) state: The …

    15 Nov 2007 · 62005CJ0319

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    By that decision, Tecfidera was authorised as a mono-substance medicinal product, composed of DMF, and indicated for the treatment of multiple sclerosis. The Commission also held that Tecfidera did not belong to the same global marketing …

    16 Mar 2023 · 62021CJ0438

  • Judgment of the Court (Second Chamber), 28 June 2012. Fabio Caronna.Decision

    Recitals 2 to 5 and 35 and 36 of the Directive are worded as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. However, this objective must be …

    28 Jun 2012 · 62011CJ0007

  • Judgment of the Court (Second Chamber) of 2 April 2009. Criminal proceedings against Frede Damgaard.Decision

    Recitals 2 and 3 in the preamble to Directive 2001/83 state the following: ‘(2) The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. (3) However, this …

    2 Apr 2009 · 62007CJ0421

  • Judgment of the Court (Third Chamber) of 11 June 2020. ratiopharm GmbH v Novartis Consumer Health GmbH.Decision

    Recitals 2 to 4, 14, 45 to 47, 50 and 51 of Directive 2001/83 are worded as follows: The essential aim of any rules governing the production, distribution and use of medicinal products must be to safeguard public health. However, this …

    11 Jun 2020 · 62018CJ0786

  • Judgment of the Court (Sixth Chamber) of 15 December 2016. LEK Farmacevtska Družba d.d. v Republika Slovenija.Decision

    Recitals 2 to 5 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67), as amended by Directive 2011/62/EU of the …

    15 Dec 2016 · 62015CJ0700

  • Opinion of Advocate General Trstenjak delivered on 21 June 2007. Commission of the European Communities v Federal Republic of Germany.Decision

    Recitals 2 to 5 of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use state: The essential aim of any rules governing the production, …

    21 Jun 2007 · 62005CC0319

  • Opinion of Advocate General Bot delivered on 12 June 2014. Markus D. and G.Decision

    The principles established by the EU legislature concerning the legislation applicable to medicinal products are based on the protection of human health and on the free movement of goods within the European Union. (22)

    12 Jun 2014 · 62013CC0358

  • Opinion of Advocate General Szpunar delivered on 18 December 2025. FARMAKEIO YZ & SIA O.E. v Ypourgos Anaptyxis kai Ependyseon and Ypourgos Decision

    Although the recitals of Directive 2001/83 mention a single objective – namely the protection of public health by combating falsified medicinal products – its provisions must be interpreted in context. The aim of that directive, which …

    18 Dec 2025 · 62024CC0604

  • Opinion of Advocate General Wahl delivered on 20 May 2014. Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra.Decision

    It follows from recital 2 in the preamble to Directive 2001/83 that the overarching aim of rules governing the production, distribution and use of medicinal products must be to safeguard public health. However, according to recital 3, this …

    20 May 2014 · 62013CC0104